<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03506113</url>
  </required_header>
  <id_info>
    <org_study_id>29-C0707</org_study_id>
    <secondary_id>UMIN000031933</secondary_id>
    <nct_id>NCT03506113</nct_id>
  </id_info>
  <brief_title>GRam Stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) Trial</brief_title>
  <official_title>GRam Stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osaka General Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chukyo Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ebina General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hitachi General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hokkaido University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kansai Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kansai Medical University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nagasaki University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saga University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of the Ryukyus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wakayama Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Osaka General Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Optimising the use of antibiotic agents is a pressing challenge to overcoming the
      rapid emergence and spread of multidrug-resistant pathogens in intensive care units (ICUs).
      Although Gram staining may possibly provide immediate information for predicting pathogenic
      bacteria, Gram stain-guided initial antibiotic treatment is not well established in the ICU
      setting. The investigators planned the GRam stain-guided Antibiotics ChoicE for
      Ventilator-Associated Pneumonia (GRACE-VAP) trial to investigate whether Gram staining can
      safely restrict the use of broad-spectrum antibiotics in patients with ventilator-associated
      pneumonia (VAP), which is one of the most common hospital-acquired infections in ICUs.

      Methods/Design: The GRACE-VAP trial is a multicenter, randomised, open-label parallel-group
      trial to assess the non-inferiority of Gram stain-guided initial antibiotic treatment to
      guidelines-based initial antibiotic treatment for the primary endpoint of clinical cure rate
      in patients with VAP. Secondary endpoints include the coverage rates of initial antibiotic
      therapies, the selected rates of anti-pseudomonal agents and anti-methicillin-resistant
      Staphylococcus aureus (MRSA) agents as initial antibiotic therapies, 28-day all-cause
      mortality, ICU-free days, ventilator-free days, and adverse events. Participants are randomly
      assigned to receive Gram stain-guided treatment or guidelines-based treatment at a ratio of
      1:1. In the Gram stain group, results of Gram staining of endotracheal aspirate are used to
      guide the selection of antibiotics. In the guidelines group, the combination of an
      anti-pseudomonal agent and anti-MRSA agent are administered. A total sample size of 200 was
      estimated to provide a power of 80% with a 1-sided alpha level of 2.5% and a non-inferiority
      margin of 20%, considering 10% non-evaluable participants.

      Discussion: The GRACE-VAP trial is expected reveal whether Gram staining can reduce the use
      of broad-spectrum antibiotics without impairing patient outcomes and thereby provide evidence
      for an antibiotics selection strategy in patients with VAP.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure of VAP</measure>
    <time_frame>up to 22 days</time_frame>
    <description>Cure is defined as completion of antibiotic therapy within 14 days, improvement or lack of progression of baseline radiographic findings at the end of therapy (EOT), and resolution of signs and symptoms of pneumonia at the follow-up/test of cure visit (FU/TOC) conducted 7 days after EOT. Failure is defined as administration of study medication for 15 days or more, progression of radiological signs of pneumonia at EOT, or relapsed pneumonia at FU/TOC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Select of anti-pseudomonal agents as initial antibiotic therapies</measure>
    <time_frame>on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Select of anti-MRSA agents as initial antibiotic therapies</measure>
    <time_frame>on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coverage of initial antibiotic therapies</measure>
    <time_frame>on day 1</time_frame>
    <description>Therapies will be considered appropriate when all pathogens isolated with at least 1+ semi-quantitative growth from endotracheal aspirates are covered by the selected antibiotic agents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-free days</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of antibiotic therapies</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of escalation or de-escalation of antibiotic therapies</measure>
    <time_frame>up to 28 days</time_frame>
    <description>The investigators evaluate whether antibiotic agents are changed during the treatments of VAP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events related to antibiotics</measure>
    <time_frame>up to 7 days after the end of therapy</time_frame>
    <description>renal impairment, thrombocytopenia, diarrhoea, Clostridium difficile infection, skin rash, and seizure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation marker</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Laboratory marker of inflammation (CRP, PCT) on 2, 4, 6, 8, and 14 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ failure control</measure>
    <time_frame>up to 14 days</time_frame>
    <description>The investigators evaluate Sequential Organ Failure Assessment (SOFA) score on 2, 4, 6, 8, and 14 days. The SOFA score is made of 6 variables, each representing an organ system ( respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems). Each organ system is assigned a point value from 0 (normal) to 4 (high degree of dysfunction/failure). The total SOFA score is calculated by the sum of each 6 variables (range, 0-24).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>up to 14 days</time_frame>
    <description>The investigators evaluate whether participants are performed a renal replacement therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ventilator Associated Pneumonia</condition>
  <arm_group>
    <arm_group_label>Gram stain-guided therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics. The results of the Gram stains are categorised as Gram-positive cocci (GPC) chains, GPC clusters, Gram-positive bacilli (GPB), Gram-negative rods (GNR), or a combination of these. A non-pseudomonal beta-lactam antibiotic is selected when the Gram stain of the endotracheal aspirate shows only GPC chains and/or GPB. An anti-MRSA agent is selected when the Gram stain results show GPC clusters without GNR. An anti-pseudomonal agent is selected when the Gram stain results show GNR without GPC clusters. The combination of an anti-pseudomonal agent and an anti-MRSA agent is selected when the Gram stain results show both GPC clusters and GNR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Guidelines-based therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are administered the combination of an anti-pseudomonal agent and anti-MRSA agent according to the Infectious Disease Society of America and the American Thoracic Society (IDSA/ATS) guidelines because 47.7% of S. aureus isolates are MRSA in Japanese ICUs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gram stain-guided antibiotic choice</intervention_name>
    <description>The results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics.</description>
    <arm_group_label>Gram stain-guided therapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guidelines-based antibiotics choice</intervention_name>
    <description>Patients are administered the combination of an anti-pseudomonal agent and anti-MRSA agent according to IDSA/ATS guidelines</description>
    <arm_group_label>Guidelines-based therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing mechanical ventilation in the ICU

          -  Patients undergoing mechanical ventilation for at least 48 hours

          -  Patients diagnosed as having VAP, which is defined by a modified clinical pulmonary
             infection score of 5 or more

        Exclusion Criteria:

          -  Patients having an allergy to study medications

          -  Pregnant patients

          -  Patients discharged from ICU

          -  Patients diagnosed as having heart failure or atelectasis

          -  Patients administered antibiotics for more than 24 hours when they meet the inclusion
             criteria

          -  Patients declined to provide full life support

          -  Patients judged as inappropriate at the discretion of the study physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jumpei Yoshimura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osaka General Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kazuma Yamakawa, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Osaka General Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Takeshi Morimoto, MD, PhD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Hyogo College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jumpei Yoshimura, MD</last_name>
    <phone>+81-6-6692-1201</phone>
    <email>jumpei.y0210@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kazuma Yamakawa, MD, PhD</last_name>
    <phone>+81-6-6692-1201</phone>
    <email>k.yamakawa0911@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chukyo Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akinori Osuka, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mineji Hayakawa, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hitachi General Hospital</name>
      <address>
        <city>Hitachi</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kensuke Nakamura, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ebina General Hospital</name>
      <address>
        <city>Ebina</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takeshi Yamagiwa, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of the Ryukyus Hospital</name>
      <address>
        <city>Nishihara</city>
        <state>Okinawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takayuki Taira, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University Hospital</name>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroki Takahashi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University Medical Center</name>
      <address>
        <city>Moriguchi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masahiro Kawada, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuhei Yamano, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka General Medical Center</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jumpei Yoshimura, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saga University Hospital</name>
      <address>
        <city>Saga</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroyuki Koami, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical University Hospital</name>
      <address>
        <city>Wakayama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyohei Miyamoto, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2018</study_first_submitted>
  <study_first_submitted_qc>April 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2018</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Osaka General Medical Center</investigator_affiliation>
    <investigator_full_name>Jumpei Yoshimura, MD</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Gram staining</keyword>
  <keyword>Antimicrobial therapy</keyword>
  <keyword>Empirical therapy</keyword>
  <keyword>Nosocomial infection</keyword>
  <keyword>Mechanical ventilation</keyword>
  <keyword>Intensive care</keyword>
  <keyword>Sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

